Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16559185 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2AACHE | |
| SCHEMBL21257334 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2AACHE | |
| SCHEMBL213020 | 1.00 | LPAR3 (0.45) | LPAR3LPAR2LPAR1PLA2G2AACHE | |
| SCHEMBL14614344 | 0.98 | LPAR3 (0.42) | LPAR3LPAR2LPAR1PLA2G2APPARD | |
| SCHEMBL16559184 | 0.91 | LPAR3 (0.39) | LPAR3LPAR2LPAR1PLA2G2APPARD | |
| SCHEMBL26434943 | 0.89 | LPAR3 (0.38) | LPAR3LPAR2LPAR1PLA2G2A | |
| SCHEMBL18104377 | 0.88 | SAT1 (0.45) | LPAR3LPAR2LPAR1PLA2G2AACHE | |
| SCHEMBL15935828 | 0.87 | LPAR3 (0.48) | LPAR3LPAR2LPAR1PLA2G2AALDH1A1 | |
| SCHEMBL10178024 | 0.87 | LPAR3 (0.48) | LPAR3LPAR2LPAR1PLA2G2AALDH1A1 | |
| SCHEMBL13912174 | 0.86 | SAT1 (0.46) | LPAR3LPAR2LPAR1PLA2G2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190247414-A1 | BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2019-08-15 | — | — | US | disclosed |
| US-20150072351-A1 | HIGH-SENSITIVITY NUCLEIC ACID PREPARATION METHODS FOR THE DETECTION OF NUCLEIC ACID BY NUCLEIC ACID POLYMERASE | BIONEER CORPORATION (KR) | 2015-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247414-A1 | BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID | FABP7, NR2E3, SREBF2 | LPAR3 477/4885LPAR2 309/4885LPAR1 653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.